… (OS) and to describe the best tumor response according to the … been observed in early-phase
trials with MEK inhibitors, even … , though no strong biological data have been reported to …

… Few articles combining immunotherapy with biological agents and clearly mentioning the
OBD have been identified (n = 3). For those particular cases, OBD was assessed using …

… whether neoadjuvant toripalimab with or without celecoxib … colorectal cancers, we found the
best estimates of the proportion of … , toripalimab in combination with celecoxib compared with …

… for optimal vaccination dosing and/or for completing the priming and three booster doses. …
shortcoming within this trial, with the αDC1 and CKM showing good biologic function. The low …

… or in combination with other nonchemotherapeutic agents such as celecoxib and thalidomide…
Future preclinical studies should focus on determination of optimum biological dosage and …

… the optimal biological dose (OBD) based on safety and efficacy. BOIN designs provide a
complete suite for dose finding in early phase trials… of a combination therapy to determine either …

… Bayesian modelling to identify the optimal biological dose of methotrexate in combination with
erlotinib and celecoxib on the … A dose of 9 mg/m2 of methotrexate weekly was identified as …

… To this end, the present study examined the biological-effect of PrimeC on exploratory …
study supports the safety and tolerability of a unique combination of ciprofloxacin and celecoxib …

… The analgesic celecoxib has long been shown to have … encouraging results in combination
with low-dose temozolomide. The … We used the best overall response, ie, the best response …

… A phase I trial to determine the optimal biological dose of celecoxib when combined with
erlotinib in advanced non-small cell lung cancer. Clinical cancer research: an official journal of …